Koers Immunoprecise Antibodies Ltd Other OTC
Aandelen
CA87588T1030
Farmaceutische producten
Omzet 2024 * | 24,59 mln. 17,96 mln. 16,78 mln. | Omzet 2025 * | 29,82 mln. 21,78 mln. 20,35 mln. | Marktkapitalisatie | 36,38 mln. 26,57 mln. 24,83 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -12 mln. -8,77 mln. -8,19 mln. | Nettowinst (verlies) 2025 * | -9 mln. -6,57 mln. -6,14 mln. | EV/omzet 2024 * | 1,48 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,22 x |
K/w-verhouding 2024 * |
-2,88
x | K/w-verhouding 2025 * |
-3,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,41% |
Recentste transcriptie over Immunoprecise Antibodies Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29-09-23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05-09-23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21-02-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,99% | 94,76 mld. | |
-4,34% | 37,58 mld. | |
-10,41% | 33,3 mld. | |
+75,79% | 27,92 mld. | |
-14,61% | 15,85 mld. | |
-3,46% | 13,79 mld. | |
-12,31% | 11,51 mld. | |
+184,77% | 10,9 mld. | |
-54,13% | 9,27 mld. |